iECURE
Karen Kuhn has a comprehensive work experience in the clinical operations and project management field. Karen is currently working as a Sr. Director of Clinical Operations at iECURE, Inc. Karen previously worked at KLM Kuhn Consulting as a Clinical Operations and Project Management Specialist. Before that, they held positions at Vor Biopharma, MedSource, Cmed Clinical Services, Ockham (now Chiltern), ReSearch Pharmaceutical Services, Ockham Development Group, Centocor, and MDS Pharma Services, where they held various leadership roles involved in clinical operations and project management.
Karen Kuhn completed their Bachelor of Science in Nursing (BSN) from Immaculata University in 2001. Prior to that, they obtained their Registered Nurse qualification from Chester County Hospital School of Nursing in 1990.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.